Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 7/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24867750 | 1.00 | APLNR (0.45) | APLNRCYP2C19PDE4APDE4BPDE4C | |
| SCHEMBL24807965 | 1.00 | APLNR (0.45) | APLNRCYP2C19PDE4APDE4BPDE4C | |
| SCHEMBL3632875 | 0.72 | APLNR (0.54) | APLNRCYP2C19KDM4EALDH1A1CYP1A2 | |
| SCHEMBL19284443 | 0.70 | APLNR (0.58) | APLNRCYP2C19KDM4EALDH1A1CYP1A2 | |
| SCHEMBL19284442 | 0.70 | APLNR (0.58) | APLNRCYP2C19KDM4EALDH1A1CYP1A2 | |
| SCHEMBL25053895 | 0.70 | — | — | |
| SCHEMBL24868336 | 0.70 | CYP2C19 (0.50) | APLNRCYP2C19PDE4APDE4BPDE4C | |
| SCHEMBL9955907 | 0.68 | APLNR (0.50) | APLNRCYP2C19KDM4EALDH1A1CYP1A2 | |
| SCHEMBL24868406 | 0.68 | CYP2C19 (0.48) | APLNRCYP2C19PDE4APDE4BPDE4C | |
| SCHEMBL17586694 | 0.68 | APLNR (0.56) | APLNRCYP2C19PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912686-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912686-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230212151-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212151-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-11584738-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20230012262-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584738-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | APLNR 103/4885CYP2C19 4398/4885PDE4A 1371/4885 |
| US-20230212151-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR4 | APLNR 103/4885CYP2C19 4398/4885PDE4A 1371/4885 |
| US-20230012262-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR4 | APLNR 103/4885CYP2C19 4398/4885PDE4A 1371/4885 |
| US-11912686-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | APLNR 103/4885CYP2C19 4398/4885PDE4A 1371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.